Literature DB >> 2489037

Thymic stroma is required for the development of human T cell lineages in vitro.

A de la Hera1, W Marston, C Aranda, M L Toribio, C Martinez.   

Abstract

Development of the T cell lineage is characterized by the homing of hematopoietic precursors to thymus, followed by their acquisition of receptors for antigen. T cell receptors are alpha beta or gamma delta heterodimers associated with CD3 (TCR-CD3). Very early T cell precursors in humans have been characterized as CD7+ 45+ cells which lack the T cell differentiation antigens CD1, CD2, CD3, CD4, and CD8. A phenotypically equivalent early thymocyte population also occurs in postnatal life, and we have previously shown that interleukin 2 (IL2) promotes the development in vitro of both the alpha beta and the gamma delta T cells from these early thymocytes. Here we have analyzed the requirements of the induction of the IL2 pathway in early thymocytes, and their developmental potential. We show that: (i) thymic stromal cells, which are present in thymocyte suspensions, are necessary to induce the IL2 pathway and the development of alpha beta or gamma delta T cell lineages from early thymocytes in vitro; and (ii) when removed from the in vivo environment, early thymocytes can develop in vitro into TCR-CD3- cells of the natural killer (NK) lineage. We conclude that CD7+ 45+, CD1-2-3-4-8- early thymocytes are multipotential progenitors that, at least, have the capacity to develop into alpha beta or gamma delta T cell and NK lineages. The analysis of the mechanisms of generation and selection of human T and NK cell diversity, not feasible in bone marrow cultures, is now possible.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2489037     DOI: 10.1093/intimm/1.5.471

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  12 in total

1.  Lymphoid precursor cell lines have capacity to migrate to multiple lymphoid sites.

Authors:  H C O'Neill; K Ni; T J O'Neill
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

2.  Maturation or differentiation of human thymocyte precursors in vitro?

Authors:  V Groh; M Fabbi; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

3.  The phenotypic heterogeneity of mouse thymic stromal cells.

Authors:  D I Godfrey; D J Izon; C L Tucek; T J Wilson; R L Boyd
Journal:  Immunology       Date:  1990-05       Impact factor: 7.397

Review 4.  In vivo models of human lymphopoiesis and autoimmunity in severe combined immune deficient mice.

Authors:  T S Barry; B F Haynes
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

5.  Expression of cytokines and their receptors by human thymocytes and thymic stromal cells.

Authors:  S S Wolf; A Cohen
Journal:  Immunology       Date:  1992-11       Impact factor: 7.397

6.  Involvement of the interleukin 4 pathway in the generation of functional gamma delta T cells from human pro-T cells.

Authors:  A Bárcena; M J Sánchez; J L de la Pompa; M L Toribio; G Kroemer; C Martínez-A
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

7.  Differentiation of CD3-4-8- human fetal thymocytes in vivo: characterization of a CD3-4+8- intermediate.

Authors:  D L Kraft; I L Weissman; E K Waller
Journal:  J Exp Med       Date:  1993-07-01       Impact factor: 14.307

8.  Proliferation of an athymic mouse-derived T-cell clone on thymic stromal cells with interleukin-2.

Authors:  H Tamura; H Kuzuhara; C Hiramine; K Hojo; H Yamamoto; S Fujimoto
Journal:  Immunology       Date:  1991-10       Impact factor: 7.397

9.  Precursors of CD3+CD4+CD8+ cells in the human thymus are defined by expression of CD34. Delineation of early events in human thymic development.

Authors:  A Galy; S Verma; A Bárcena; H Spits
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

10.  Human natural killer cell committed thymocytes and their relation to the T cell lineage.

Authors:  M J Sánchez; H Spits; L L Lanier; J H Phillips
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.